Publications

 

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.

Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D, Haffner I, Schierle K, Weirich G, Luber B.

Mol Oncol. 2018 Apr;12(4):441-462. doi: 10.1002/1878-0261.12170. Epub 2018 Mar 10.

PMID:29325228

 

Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis.

Keller S, Kneissl J, Grabher-Meier V, Heindl S, Hasenauer J, Maier D, Mattes J, Winter P, Luber B.

BMC Cancer. 2017 Dec 13;17(1):845. doi: 10.1186/s12885-017-3822-3.

PMID:29237412

 

PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI.

Urban C, Buck A, Siveke JT, Lordick F, Luber B, Walch A, Aichler M.

Biochim Biophys Acta Gen Subj. 2018 Jan;1862(1):51-60. doi: 10.1016/j.bbagen.2017.10.005. Epub 2017 Oct 9.

PMID:29024724

 

Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome.

Kunzke T, Balluff B, Feuchtinger A, Buck A, Langer R, Luber B, Lordick F, Zitzelsberger H, Aichler M, Walch A.

Oncotarget. 2017 Jul 10;8(40):68012-68025. doi: 10.18632/oncotarget.19137. eCollection 2017 Sep 15.

PMID:28978092

 

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.

Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, Zwingenberger G, Weichert W, Luber B.

J Cancer Res Clin Oncol. 2017 Apr;143(4):573-600. doi: 10.1007/s00432-016-2308-z. Epub 2016 Dec 8.

PMID:27933395

 

Associating approximate paths and temporal sequences of noisy detections: Application to the recovery of spatio-temporal cancer cell trajectories.

Dorfer M, Kazmar T, Šmíd M, Sing S, Kneißl J, Keller S, Debeir O, Luber B, Mattes J.

Med Image Anal. 2016 Jan;27:72-83. doi: 10.1016/j.media.2015.03.007. Epub 2015 Apr 29.

PMID:25987193

 

Proteomic and metabolic prediction of response to therapy in gastric cancer.

Aichler M, Luber B, Lordick F, Walch A.

World J Gastroenterol. 2014 Oct 14;20(38):13648-57. doi: 10.3748/wjg.v20.i38.13648.

PMID:25320503

 

Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.

Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A.

Oncotarget. 2014 Aug 30;5(16):6620-32.

PMID:25216514

 

Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma.

Feuchtinger A, Stiehler T, Jütting U, Marjanovic G, Luber B, Langer R, Walch A.

Histochem Cell Biol. 2015 Jan;143(1):1-9. doi: 10.1007/s00418-014-1258-2. Epub 2014 Aug 26.

PMID:25156293

 

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.

Kneissl J, Keller S, Lorber T, Heindl S, Keller G, Drexler I, Hapfelmeier A, Höfler H, Luber B.

Int J Oncol. 2012 Aug;41(2):733-44. doi: 10.3892/ijo.2012.1479. Epub 2012 May 14.

PMID:22614881

 

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.

Heindl S, Eggenstein E, Keller S, Kneissl J, Keller G, Mutze K, Rauser S, Gasteiger G, Drexler I, Hapfelmeier A, Höfler H, Luber B.

J Cancer Res Clin Oncol. 2012 Jan 31. [Epub ahead of print]

PMID:22290393

 

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F.

BMC Cancer. 2011 Dec 7;11:509. doi: 10.1186/1471-2407-11-509.

PMID:22152101

 

Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy.

Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D.

Cancer Res. 2011 Sep 1;71(17):5670-7. doi: 10.1158/0008-5472.CAN-11-0268. Epub 2011 Aug 16.

PMID:21846824

 

Learning cellular texture features in microscopic cancer cell images for automated cell-detection.

Kazmar T, Smid M, Fuchs M, Luber B, Mattes J.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:49-52. doi: 10.1109/IEMBS.2010.5626299.

PMID:21095879

 

Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.

Mutze K, Langer R, Becker K, Ott K, Novotny A, Luber B, Hapfelmeier A, Göttlicher M, Höfler H, Keller G.

Ann Surg Oncol. 2010 Dec;17(12):3336-43. doi: 10.1245/s10434-010-1182-1. Epub 2010 Jun 29.

PMID:20585871

 

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C.

Br J Cancer. 2010 Feb 2;102(3):500-5. doi: 10.1038/sj.bjc.6605521. Epub 2010 Jan 12.

PMID:20068568

 

Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation.

Deplazes J, Fuchs M, Rauser S, Genth H, Lengyel E, Busch R, Luber B.

Hum Mol Genet. 2009 Oct 1;18(19):3632-44. doi: 10.1093/hmg/ddp312. Epub 2009 Jul 7.

PMID:19584084

 

Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.

Ruseva Z, Geiger PX, Hutzler P, Kotzsch M, Luber B, Schmitt M, Gross E, Reuning U.

Exp Cell Res. 2009 Jun 10;315(10):1759-71. doi: 10.1016/j.yexcr.2009.01.007. Epub 2009 Jan 22.

PMID:19371633

 

E-cadherin mutations and cell motility: a genotype-phenotype correlation.

Mateus AR, Simões-Correia J, Figueiredo J, Heindl S, Alves CC, Suriano G, Luber B, Seruca R.

Exp Cell Res. 2009 May 1;315(8):1393-402. doi: 10.1016/j.yexcr.2009.02.020. Epub 2009 Mar 4.

PMID:19268661

 

Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.

Aubele M, Walch AK, Ludyga N, Braselmann H, Atkinson MJ, Luber B, Auer G, Tapio S, Cooke T, Bartlett JM.

Br J Cancer. 2008 Oct 7;99(7):1089-95. doi: 10.1038/sj.bjc.6604660. Epub 2008 Sep 9.

PMID:18781181

 

Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer.

Walch A, Seidl S, Hermannstädter C, Rauser S, Deplazes J, Langer R, von Weyhern CH, Sarbia M, Busch R, Feith M, Gillen S, Höfler H, Luber B.

Mod Pathol. 2008 May;21(5):544-52. doi: 10.1038/modpathol.2008.3. Epub 2008 Feb 1.

PMID:18246045

 

Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.

Bremm A, Walch A, Fuchs M, Mages J, Duyster J, Keller G, Hermannstädter C, Becker KF, Rauser S, Langer R, von Weyhern CH, Höfler H, Luber B.

Cancer Res. 2008 Feb 1;68(3):707-14. doi: 10.1158/0008-5472.CAN-07-1588.

PMID:18245470

 

Deletion of exon 8 increases cisplatin-induced E-cadherin cleavage.

Fuchs M, Hermannstädter C, Hutzler P, Häcker G, Haller F, Höfler H, Luber B.

Exp Cell Res. 2008 Jan 1;314(1):153-63. Epub 2007 Sep 14.

PMID:17959171

 

EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells.

Mateus AR, Seruca R, Machado JC, Keller G, Oliveira MJ, Suriano G, Luber B.

Hum Mol Genet. 2007 Jul 1;16(13):1639-47. Epub 2007 May 17.

PMID:17510211

 

Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer.

Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, Hermannstädter C, Quintanilla-Martinez L, Busch R, Höfler H, Fend F, Luber B.

J Clin Pathol. 2007 Jul;60(7):756-61. Epub 2007 May 4.

PMID:17483253

 

Methods to analyze the effects of the urokinase system on cancer cell adhesion, proliferation, migration, and signal transduction events.

Reuning U, Schmitt M, Luber B, Beck V, Magdolen V.

Methods Mol Med. 2006;120:427-40.

PMID:16491616

 

E-cadherin expression in sporadic gastric cancer from Mexico: exon 8 and 9 deletions are infrequent events associated with poor survival.

Gamboa-Dominguez A, Dominguez-Fonseca C, Chavarri-Guerra Y, Vargas R, Reyes-Gutierrez E, Green D, Quintanilla-Martinez L, Luber B, Busch R, Becker KF, Becker I, Höfler H, Fend F.

Hum Pathol. 2005 Jan;36(1):29-35.

PMID:15712179

 

ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.

Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H, Kessler H, Schmitt M, Geppert HG, Reuning U.

Int J Biochem Cell Biol. 2005 Mar;37(3):590-603.

PMID:15618016

 

Effect of tumor-associated mutant E-cadherin variants with defects in exons 8 or 9 on matrix metalloproteinase 3.

Fuchs M, Hermannstädter C, Specht K, Knyazev P, Ullrich A, Rosivatz E, Busch R, Hutzler P, Höfler H, Luber B.

J Cell Physiol. 2005 Mar;202(3):805-13.

PMID:15389640

 

Dynamics of cell adhesion and motility in living cells is altered by a single amino acid change in E-cadherin fused to enhanced green fluorescent protein.

Fuchs M, Hutzler P, Handschuh G, Hermannstädter C, Brunner I, Höfler H, Luber B.

Cell Motil Cytoskeleton. 2004 Sep;59(1):50-61.

PMID:15259055

 

Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide, and 5-fluorouracil.

Fricke E, Hermannstädter C, Keller G, Fuchs M, Brunner I, Busch R, Höfler H, Becker KF, Luber B.

Oncology. 2004;66(2):150-9.

PMID:15138368

 

Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system.

Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, Busch R, Hermannstädter C, Nährig J, Becker KF, Becker I, Höfler H, Fend F, Luber B.

Mod Pathol. 2004 May;17(5):579-87.

PMID:15073595

 

Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.

Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Höfler H, Schmitt M, Reuning U.

Biol Chem. 2003 Jul;384(7):1073-83.

PMID:12956424

 

Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis.

Kremer M, Quintanilla-Martinez L, Fuchs M, Gamboa-Dominguez A, Haye S, Kalthoff H, Rosivatz E, Hermannstädter C, Busch R, Höfler H, Luber B.

Carcinogenesis. 2003 Dec;24(12):1879-86. Epub 2003 Aug 29.

PMID:12949051

 

Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma.

Fricke E, Keller G, Becker I, Rosivatz E, Schott C, Plaschke S, Rudelius M, Hermannstädter C, Busch R, Höfler H, Becker KF, Luber B.

Int J Cancer. 2003 Mar 10;104(1):60-5.

PMID:12532420

 

Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.

Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Höfler H, Becker KF.

Am J Pathol. 2002 Nov;161(5):1881-91.

PMID:12414534

 

Motility enhancement by tumor-derived mutant E-cadherin is sensitive to treatment with epidermal growth factor receptor and phosphatidylinositol 3-kinase inhibitors.

Fuchs M, Hutzler P, Brunner I, Schlegel J, Mages J, Reuning U, Hapke S, Duyster J, Hirohashi S, Genda T, Sakamoto M, Uberall F, Höfler H, Becker KF, Luber B.

Exp Cell Res. 2002 Jun 10;276(2):129-41.

PMID:12027444

 

Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences.

Handschuh G, Luber B, Hutzler P, Höfler H, Becker KF.

J Mol Biol. 2001 Nov 30;314(3):445-54.

PMID:11846558

 

Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate.

Luber B, Candidus S, Handschuh G, Mentele E, Hutzler P, Feller S, Voss J, Höfler H, Becker KF.

Cell Adhes Commun. 2000 May;7(5):391-408.

PMID:10830618

 

Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility.

Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, Birchmeier W, Höfler H, Becker KF.

Oncogene. 1999 Jul 29;18(30):4301-12.

PMID:10439038

 

The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines.

Bergametti F, Prigent S, Luber B, Benoit A, Tiollais P, Sarasin A, Transy C.

Oncogene. 1999 May 6;18(18):2860-71.

PMID:10362257

 

Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro.

Luber B, Arnold N, Stürzl M, Höhne M, Schirmacher P, Lauer U, Wienberg J, Hofschneider PH, Kekulé AS.

Oncogene. 1996 Apr 18;12(8):1597-608.

PMID:8622879

 

The hepatitis B virus transactivator HBx causes elevation of diacylglycerol and activation of protein kinase C.

Luber B, Lauer U, Weiss L, Höhne M, Hofschneider PH, Kekulé AS.

Res Virol. 1993 Jul-Aug;144(4):311-21.

PMID:8210715

 

Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway.

Kekulé AS, Lauer U, Weiss L, Luber B, Hofschneider PH.

Nature. 1993 Feb 25;361(6414):742-5.

PMID:8441471

 

Multiple simian virus 40 enhancer elements mediate the trans-activating function of the X protein of hepatitis B virus.

Luber B, Bürgelt E, Fromental C, Kanno M, Koch W.

Virology. 1991 Oct;184(2):808-13.

PMID:1653503